Skip to main content
ISTH 2023 Main banner
Back

    Poster Networking

    COVID

    Poster Networking Session

    PB0613 - IL-6 dosage by ELISA tests in patients after COVID-19 infection: significant correlation between length of hospitalization and permanently altered levels of interleukin-6

    Monday, June 26, 2023
    18:30 – 19:30 ET
    Room: Exhibition

      Presenting Author(s)

    • Alessandra N. L Prezotti, MD, MsC, pHD (she/her/hers)

      Coordinator of Hemostasis Center of HEMOES
      Centro de Hematologia e Hemoterapia do Espirito Santo (HEMOES)
      Vitoria, Espirito Santo, Brazil

      • Co-Author(s)

    • DC

      Danielle Ribeiro Campos da Silva

      Pharmacist and Biochemistry
      Centro de Hemoterapia e Hematologia do Espírito Santo (HEMOES)
      Vitória, Espirito Santo, Brazil

    • HV

      Helena Serafim da Vitória

      Student
      Universidade Federal do Espírito Santo (UFES)
      Vitória, Espirito Santo, Brazil

    • AZ

      Alexia Zetum

      Biologist
      Universidade Federal do Espírito Santo (UFES)
      Vitória, Espirito Santo, Brazil

    • HR

      Henrique Rosa

      Student
      Universidade Vila Velha (UVV)
      Vitória, Espirito Santo, Brazil

    • VV

      Vinícius Ventorim

      Student
      Universidade Vila Velha (UVV)
      Vitória, Espirito Santo, Brazil

    • EV

      Elizabel Vargas

      CLINICAL ANALYSIS TECHNICIAN
      Centro de Hemoterapia e Hematologia do Espírito Santo (HEMOES)
      Vitória, Espirito Santo, Brazil

    • LA

      Lyvia Alves

      Biologist
      Universidade Federal do Espírito Santo (UFES)
      Vitória, Espirito Santo, Brazil

    • RN

      Renata Netto

      Pharmacist
      Centro de Hemoterapia e Hematologia do Espírito Santo (HEMOES)
      Vitória, Espirito Santo, Brazil

    • DM

      Débora Meira

      TEACHER AND RESEACHER
      Universidade Federal do Espírito Santo (UFES)
      Vitória, Espirito Santo, Brazil

    • MC

      Matheus Casotti

      Student
      Universidade Federal do Espírito Santo (UFES)
      Vitória, Espirito Santo, Brazil

    • RR

      Raquel Reis

      Biologist
      Universidade Federal do Espírito Santo (UFES)
      Vitória, Espirito Santo, Brazil

    • SM

      Sibia Marcondes

      medical doctor
      HEMOES
      Vitoria, Espirito Santo, Brazil

    • DR

      Debora Rocha

      study coordinator
      Centro de Hematologia e Hemoterapia do Espirito Santo (HEMOES)
      Vitoria, Espirito Santo, Brazil

    • AR

      Antonio Rocha-Neto

      study coordinator
      HEMOES
      Vitoria, Espirito Santo, Brazil

    • NS

      Nathalya Santos

      Pharmacist
      Universidade Federal do Espírito Santo (UFES)
      Vitória, Espirito Santo, Brazil

    • JD

      Juliana Duarte

      Doctor
      Centro de Hemoterapia e Hematologia do Espírito Santo (HEMOES)
      Vitória, Espirito Santo, Brazil

    • MO

      Maria Orletti

      Pharmacist
      Centro de Hemoterapia e Hematologia do Espírito Santo (HEMOES)
      Vitória, Espirito Santo, Brazil

    • LR

      Lilyan Resende

      CLINICAL ANALYSIS TECHNICIAN
      Centro de Hemoterapia e Hematologia do Espírito Santo (HEMOES)
      Vitória, Espirito Santo, Brazil

    • IL

      Iúri Drumond Louro

      Teacher, Principal Researcher and Medical doctor
      Universidade Federal do Espírito Santo (UFES)
      Vitória, Espirito Santo, Brazil

    Background: The severity of coronavirus disease-19 (COVID-19) is related to an increase in inflammatory cytokines, including interleukin-6 (IL-6). This interleukin is found at elevated levels during a SARS-CoV-2 infection.

    Aims: The objective of this study was to evaluate the level of IL-6 serum in post infection patients and verify the permanence of altered IL6 in people who have already been infected. In addition to associating them with the severity of the disease.

    Methods: The samples of 226 volunteers were analyzed. The research was approved by the ethics committee (N. 6 37094020.6.0000.5060). Volunteers were not vaccinated and tested positive for at least 30 days. They were divided into 3 groups (THE WHO): A: symptoms mild, less than 14 days; B: moderate, more than 14 days, which required medical support, but the level of oxygen therapy was low flow; C: Serious/severe, more than 15 days that required hospitalization and non-invasive high-flow oxygenation level or intubation. The ELISA sandwich test was used to measure serum IL6 levels. For data analysis the GraphPad Prism 8.0 program was used. Dunn's Multiple Comparison Test was used to establish differences between groups and the Multiple Linear Regression Test was used to relate IL-6 concentration in the hospitalization group with length of stay (P < 0.05 significant).

    Results: There were no statistically significant between the groups (P >0.9999). However, there was a significant correlation between length of hospitalization and permanently altered levels of IL-6 (P < 0,0001).

    Conclusion(s): Serum levels of interleukin-6 did not differ between the studied groups. The relationship between disease severity and IL6 is associated with the acute phase of the infection, however, Inflammatory imbalance was related to length of stay. A joint assessment with other inflammatory markers is important for a better understanding of the long-term consequences of SARS-CoV-2 infection.